PTK7 ADC
Genmab Halts PRO1107 and the Evolving PTK7 ADC Landscape
Explore the evolving PTK7 ADC field as Genmab halts PRO1107 and Pfizer/AbbVie discontinue cofetuzumab pelidotin, while Kelun’s SKB518 advances into Phase II and Lilly joins with LY4175408 alongside Day One’s DAY301.